Product name

Peptides for differential modulation of proteasomal activity

Summary

Using the inhibiting peptides, various pathological processes such as inflammation, autoimmunity, neurodegenerative and malignant diseases can be influenced.

Organization name

IPAL GmbH

Profile

The technology relates to peptides with regulatory influence on proteasomes that are characterized by the existence of a sequence motif of the human telomerase reverse transcriptase (hTERT).

The proteasome is involved in a variety of proteolytic degradation processes such as degradation of misfolded proteins, generation of MHC class I restricted peptides, the processing of tumor antigens, cytoplasmic pathogens and endogenous proteins.

The proteasome can be inhibited in vitro as well as in vivo. Therefore the technology is suitable for use in research as well as in the hospital.

Advantages

• Side effects of other protease inhibitors are reduced
• Wide range of indications
• Use in research (analysis and regulation of the proteasome) as well as in the hospital (tumor therapy, neurodegenerative diseases, cardiologic indications, autoimmunity, inflammation)
• Advantageous applicability, because the examined peptides have a regulatory effect, but they are not degraded by the proteasome.

A German patent application was filed.

The technology was developed at the Charité (Berlin/Germany) and is offered by IPAL.

IPAL GmbH 
Dr. Christian Wunsch 
christian.wunsch(at)ipal.de

About IPAL 

The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.

Description File

 05121_proteasome_inhibitors.pdf

URL

http://www.ipal.de/en/technology_offers/life_sciences/

Your feedback

back

Search

Sector

--- select from list ---AgroBiotechnologyBiomedicine, DiagnosticsCosmeticsEnabling Technology, Platform TechnologyEnvironmentalFine ChemicalsFoodMedical DeviceProduction, Development ServicesVeterinary

Technology

--- select from list ---AnalyticalAnimal ModelAntibody BasedAntisense, NucleotideBioinformaticBiologicalBlood Products, SubstitutesBreeding, CultivationChemistryClinical Research ServicesCompound LibrariesDiagnostic Assay, KitDrug DeliveryDrug DiscoveryDrugs, Small MoleculeEngineeringEnzymesGene Therapy, VectorsGenomicsHigh Throughput ScreeningImagingImplantIndustrial Waste Treatment, RemediationNanotechnologyNatural ProductsPeptides, ProteinsPharmacogenomicsPreclinical Research ServiceProteomicsReagents, Media RegenerationRenewable resourcesSurgical InstrumentationTissue Engineering, BiomaterialTransgenic OrganismTransplantVaccines

Development Stage

--- select from list ---Clinical Phase IClinical Phase IIClinical Phase IIIClinical Phase IV/MarketedIdea, Conceptin-vitro TestingLead Compound/SeriesPreclinicalProof-of-principlePrototypeRepurposingTarget Identification, Validation, Drug Discovery

Disease Category

--- select from list ---(Auto) ImmuneCancerous, neoplasmaticInfectious, ParasiticInflammatoryInherited, NeonatalMetabolic, EndocrineOther, organ-specific diseases

Organ

--- select from list ---BloodBoneBrainBreastCardiovascularCartilageCNS, Nerves, SpineEarEsophagusEyeGynecologyHeartImmune SystemIntestineLiverMusclePancreasPNSProstate and male sexual healthPsychiatry, psychologyRespiratorySkinTeethUrology, kidney